Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4110899 | 1.00 | CNR2 (1.00) | CNR2CNR1 | |
| SCHEMBL4109243 | 1.00 | CNR2 (1.00) | CNR2CNR1 | |
| SCHEMBL4115808 | 0.85 | CNR2 (1.00) | CNR2CNR1 | |
| SCHEMBL4110075 | 0.85 | CNR2 (1.00) | CNR2CNR1 | |
| SCHEMBL4102730 | 0.85 | CNR2 (1.00) | CNR2CNR1 | |
| SCHEMBL4113024 | 0.84 | CNR2 (0.72) | CNR2CNR1 | |
| SCHEMBL4115449 | 0.84 | CNR2 (0.72) | CNR2CNR1 | |
| SCHEMBL4108174 | 0.84 | CNR2 (0.72) | CNR2CNR1 | |
| SCHEMBL4104524 | 0.77 | CNR1 (1.00) | CNR2CNR1 | |
| SCHEMBL29370372 | 0.77 | CNR1 (1.00) | CNR2CNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250360137-A1 | ENHANCEMENT OF THE EFFICACY OF SEROTONERGIC PSYCHEDELIC DRUGS IN THE TREATMENT OR PREVENTION OF CERTAIN NEUROPSYCHIATRIC DISORDERS THROUGH INHIBITION OF TYPE-9 PHOSPHODIESTERASES | FREEDOM BIOSCIENCES INC (US) | 2025-11-27 | — | — | US | claimed |
| EP-4618980-A1 | ENHANCEMENT OF THE EFFICACY OF SEROTONERGIC PSYCHEDELIC DRUGS IN THE TREATMENT OR PREVENTION OF CERTAIN NEUROPSYCHIATRIC DISORDERS THROUGH INHIBITION OF TYPE-9 PHOSPHODIESTERASES | Freedom Biosciences, Inc. (US) | 2025-09-24 | — | — | EP | claimed |
| WO-2024107445-A1 | ENHANCEMENT OF THE EFFICACY OF SEROTONERGIC PSYCHEDELIC DRUGS IN THE TREATMENT OR PREVENTION OF CERTAIN NEUROPSYCHIATRIC DISORDERS THROUGH INHIBITION OF TYPE-9 PHOSPHODIESTERASES | FREEDOM BIOSCIENCES, INC. (US) | 2024-05-23 | — | — | WO | claimed |
| EP-1846364-A1 | NEW POTENT AND SELECTIVE LIGANDS OF CANNABINOID RECEPTORS | Universita' Degli Studi di Siena (IT) | 2007-10-24 | — | — | EP | claimed |
| WO-2006080040-A1 | NEW POTENT AND SELECTIVE LIGANDS OF CANNABINOID RECEPTORS | UNIVERSITÀ DEGLI STUDI DI SIENA (IT) | 2006-08-03 | — | — | WO | claimed |
| US-20260102502-A1 | CANNABINOID DENDRIMER COMPOSITIONS FOR TARGETED DELIVERY | UNIV JOHNS HOPKINS (US) | 2026-04-16 | — | — | US | disclosed |
| US-20250360137-A1 | ENHANCEMENT OF THE EFFICACY OF SEROTONERGIC PSYCHEDELIC DRUGS IN THE TREATMENT OR PREVENTION OF CERTAIN NEUROPSYCHIATRIC DISORDERS THROUGH INHIBITION OF TYPE-9 PHOSPHODIESTERASES | FREEDOM BIOSCIENCES INC (US) | 2025-11-27 | — | — | US | disclosed |
| EP-4618980-A1 | ENHANCEMENT OF THE EFFICACY OF SEROTONERGIC PSYCHEDELIC DRUGS IN THE TREATMENT OR PREVENTION OF CERTAIN NEUROPSYCHIATRIC DISORDERS THROUGH INHIBITION OF TYPE-9 PHOSPHODIESTERASES | Freedom Biosciences, Inc. (US) | 2025-09-24 | — | — | EP | disclosed |
| US-12404293-B2 | Method for producing glycan, building block for gylican synthesis, and compound | NATIONAL UNIVERSITY CORPORATION TOTTORI UNIVERSITY (JP) | 2025-09-02 | — | — | US | disclosed |
| EP-4157215-B1 | METHOD FOR SOLUBILIZING NATURAL, ENDOGENOUS AND SYNTHETIC CANNABINOIDS | ATHENION AG (CH) | 2025-07-30 | — | — | EP | disclosed |
| EP-4577247-A1 | CANNABINOID DENDRIMER COMPOSITIONS FOR TARGETED DELIVERY | The Johns Hopkins University (US) | 2025-07-02 | — | — | EP | disclosed |
| US-12324435-B2 | Combination of novel nitrification inhibitors and herbicides as well as combination of (thio)phosphoric acid triamides and herbicides | BASF SE (DE) | 2025-06-10 | — | — | US | disclosed |
| EP-4157215-A1 | METHOD FOR SOLUBILIZING NATURAL, ENDOGENOUS AND SYNTHETIC CANNABINOIDS | Athenion AG (CH) | 2023-04-05 | — | — | EP | disclosed |
| US-11513132-B2 | Solid phase extraction, derivatization with crown ethers, and mass spectrometry, methods, reagents and kits | TECAN SP, INC. (US) | 2022-11-29 | — | — | US | disclosed |
| EP-2295529-B2 | Use of a volatile environmental pollutants-decreasing working fluid for decreasing the amount of pollutants in a fat for alimentary or cosmetic use | BASF AS (NO) | 2022-05-18 | — | — | EP | disclosed |
| US-20220117231-A1 | Combination of Novel Nitrification Inhibitors and Herbicides as Well as Combination of (Thio)Phosphoric Acid Triamides and Herbicides | BASF SE (DE) | 2022-04-21 | — | — | US | disclosed |
| EP-3674087-B1 | INKJET LIQUID COMPOSITION | KAO CORP (JP) | 2022-04-20 | — | — | EP | disclosed |
| US-20090043129-A1 | POTENT AND SELECTIVE LIGANDS OF CANNABINOID RECEPTORS | UNIVERSITA DEGLI STUDI DI SIENA (IT) | 2009-02-12 | — | — | US | disclosed |
| EP-1846364-A1 | NEW POTENT AND SELECTIVE LIGANDS OF CANNABINOID RECEPTORS | Universita' Degli Studi di Siena (IT) | 2007-10-24 | — | — | EP | disclosed |
| WO-2006080040-A1 | NEW POTENT AND SELECTIVE LIGANDS OF CANNABINOID RECEPTORS | UNIVERSITÀ DEGLI STUDI DI SIENA (IT) | 2006-08-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12324435-B2 | Combination of novel nitrification inhibitors and herbicides as well as combination of (thio)phosphoric acid triamides and herbicides | NMT2, NAPRT, NAMPT | CNR2 2003/4885CNR1 2951/4885 |
| US-20220117231-A1 | Combination of Novel Nitrification Inhibitors and Herbicides as Well as Combination of (Thio)Phosphoric Acid Triamides and Herbicides | NMT2, NAPRT, NAMPT | CNR2 2003/4885CNR1 2951/4885 |
| US-20090043129-A1 | POTENT AND SELECTIVE LIGANDS OF CANNABINOID RECEPTORS | CNR2, CNR1, GPR18 | CNR2 1/4885CNR1 2/4885 |
| US-20250360137-A1 | ENHANCEMENT OF THE EFFICACY OF SEROTONERGIC PSYCHEDELIC DRUGS IN THE TREATMENT OR PREVENTION OF CERTAIN NEUROPSYCHIATRIC DISORDERS THROUGH INHIBITION OF TYPE-9 PHOSPHODIESTERASES | PDE9A, PDE3A, PDE2A | CNR2 204/4885CNR1 221/4885 |
| US-11513132-B2 | Solid phase extraction, derivatization with crown ethers, and mass spectrometry, methods, reagents and kits | CYP2C8, CES2, UGT1A8 | CNR2 837/4885CNR1 822/4885 |
| US-20260102502-A1 | CANNABINOID DENDRIMER COMPOSITIONS FOR TARGETED DELIVERY | CNR1, CNR2, GPR18 | CNR2 2/4885CNR1 1/4885 |
| US-12404293-B2 | Method for producing glycan, building block for gylican synthesis, and compound | OSTC, GYPA, AGL | CNR2 4797/4885CNR1 4837/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.